LifeVantage Corporation — Form 10-Q Summary
Reporting period: The filing is for the quarter ended March 31, 2023 (LifeVantage fiscal 2023 third quarter), and reports nine-month results for the period ended March 31, 2023. The request metadata’s “2022 Q3” does not match the filing period.
Business context and results
LifeVantage sells nutritional supplements, personal-care and related products through a direct-selling network of independent consultants and customers. The company operates in one segment, across the Americas and Asia/Pacific & Europe.
| Metric | Three months ended March 31 | Nine months ended March 31 |
|---|---|---|
| Revenue | $53.7 million, up 7.5% from $50.0 million | $159.2 million, up 2.4% from $155.4 million |
| Gross profit / margin | $43.1 million / 80.2%, versus $40.3 million / 80.7% | $126.9 million / 79.7%, versus $126.7 million / 81.5% |
| Operating income | $1.6 million, versus $1.8 million | $1.7 million, versus $6.1 million |
| Net income | $1.0 million, versus $1.1 million; diluted EPS $0.08 versus $0.09 | $0.6 million, versus $4.5 million; diluted EPS $0.05 versus $0.34 |
| Operating cash flow | Nine months: $3.1 million, versus $5.2 million |
Quarterly revenue growth was driven by the Americas, especially the United States. Americas revenue rose 18.2% for the quarter and 10.5% for nine months; Asia/Pacific & Europe revenue fell 14.2% and 14.3%, respectively. Foreign exchange reduced revenue by about $1.5 million in the quarter and $6.7 million for nine months. Nine-month earnings declined substantially despite modest revenue growth, reflecting lower gross margin and higher operating expenses.
Financial position and liquidity
- At March 31, 2023, cash and cash equivalents were $19.5 million, compared with $20.2 million at June 30, 2022; working capital was $22.9 million, versus $21.2 million.
- Cash flow from operations was $3.1 million; capital expenditures were $2.6 million; cash dividends paid were $1.1 million. Cash declined by $0.7 million over the nine-month period.
- No term-loan or revolving-facility borrowings were outstanding. The credit facility provides a revolving commitment of up to $5.0 million and matures March 31, 2024. The company reported covenant compliance at quarter-end.
- Operating lease liabilities totaled $13.7 million on the balance sheet. Contractual obligations also include $11.5 million of other operating commitments, primarily marketing/sponsorship and inventory purchases.
Material developments, outlook and risks
- A new Evolve compensation plan took effect March 1, 2023 in the United States, Japan, Australia and New Zealand. Management plans further market rollouts; the filing notes that plan changes may affect consultant retention, costs and results.
- The company closed its China cross-border e-commerce business on March 15, 2023. Management attributed Asia/Pacific & Europe weakness to lower active accounts and foreign exchange, while noting continued encouragement from the Philippines launch.
- Active consultants declined 6.5% year over year to 58,000 and active customers declined 4.2% to 91,000. Total active accounts fell 5.1% to 149,000, with the largest regional account decline in Asia/Pacific & Europe.
- SG&A rose to $17.7 million (33.0% of revenue) in the quarter and $54.0 million (33.9%) for nine months. The company cited event and travel costs, compensation and professional services for company-wide initiatives. The nine-month period included $0.4 million of costs associated with showroom abandonment and operational changes in Hong Kong and Singapore.
- Management believes cash and operating cash flow will fund requirements for at least the next 12 months. No quantitative revenue or earnings guidance is provided. A new $75 million shelf registration became effective April 6, 2023, providing potential access to capital, not a commitment to raise funds.
- The class action lawsuit described in the filing was dismissed with prejudice on December 15, 2022. Management reported no probable loss contingencies requiring accrual or disclosure. Principal risks include retaining consultants and customers, product acceptance and supply/inventory management, regulation of direct selling and CBD products, foreign exchange exposure, and compliance with credit covenants.
Investor verification priorities
- Check whether the new compensation plan and product launches improve consultant/customer activity and revenue, particularly in Asia/Pacific & Europe.
- Assess the persistence of gross-margin pressure, higher SG&A and the sharp decline in nine-month operating income and net income.
- Monitor operating cash generation, inventory growth, lease and other contractual commitments, and compliance with credit-facility covenants.
- Verify the financial and operating consequences of the China business closure and the impact of currency movements.
- Review the terms and potential dilution or financing implications of the $75 million shelf registration and the company’s dividend and repurchase authorizations.